---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061466"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:35:59.268097+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics completes cGMP production run for two product candidates

## Summary
- Successfully produced two product candidates using a two-tiered cGMP cell banking system from a single pluripotent cell line.
- System uses a genetically-stable master cell bank to generate a working cell bank for final product.
- Company states the process could enable millions of doses of consistent, cost-effective allogeneic cell therapy.
- Risk factor added: no assurance of consistent cGMP manufacturing at commercial scale or cost-effectiveness.

## SEC filing metadata
- accession: 0000950170-25-061466
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025061466/0000950170-25-061466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025061466/lctx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061466
- JSON: https://secwatch.observer/filing/0000950170-25-061466.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.